These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19888513)

  • 21. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
    Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
    Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
    Lu JP; Knudson MM; Bir N; Kallet R; Atkinson K
    J Am Coll Surg; 2009 Nov; 209(5):589-94. PubMed ID: 19854398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandalà M; Ciccarese M; Papaldo P; Fabi A; Cognetti F
    Thromb Res; 2007; 119(4):525-9. PubMed ID: 16780933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fondaparinux: an update on new study results.
    Bauersachs RM
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient synthesis of Idraparinux, the anticoagulant pentasaccharide.
    Chen C; Yu B
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3875-9. PubMed ID: 19386495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
    Vardi M; Laor A; Bitterman H
    Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials.
    Wan S; Quinlan DJ; Agnelli G; Eikelboom JW
    Circulation; 2004 Aug; 110(6):744-9. PubMed ID: 15262836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.
    Savi P; Herault JP; Duchaussoy P; Millet L; Schaeffer P; Petitou M; Bono F; Herbert JM
    J Thromb Haemost; 2008 Oct; 6(10):1697-706. PubMed ID: 18647228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
    Hull RD; Pineo GF; Stein P
    Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale.
    Driguez PA; Potier P; Trouilleux P
    Nat Prod Rep; 2014 Aug; 31(8):980-9. PubMed ID: 24705477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term management of patients after venous thromboembolism.
    Kearon C
    Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.